10:20 AM EST, 01/17/2025 (MT Newswires) -- Zai Lab ( ZLAB ) said Friday that its new drug application for KarXT to treat adult patients with schizophrenia was accepted by China's National Medical Products Administration.

The application is backed by results from a phase 1 China pharmacokinetics study, the phase 3 China study and data from global Emergent clinical programs, according to the company.

KarXT, or xanomeline and trospium chloride, showed a reduction in positive and negative syndrome scale total score from baseline in the China phase 3 study, Zai Lab ( ZLAB ) added.

Shares of Zai Lab ( ZLAB ) were up 2.1% in recent trading.

Price: 25.91, Change: +0.53, Percent Change: +2.09